A Study to Evaluate How VI-0521 Affect Psychomotor Performance in Healthy Overweight and Obese Subjects. - NCT00806260-68502 (Clinical Trial 258647)
Permalink: http://www.ClinicalConnection.com/exp/ExpandedPatientViewStudy258647.aspx
|
** Please review additional "Nearby Studies" on right ----->
This is an archived study that is no longer available, if you
would like to find active studies please
search our studies.
|
|
 |
 |
|
| City: |
|
Lincoln |
|
State:
|
|
NE |
| Zip Code: |
|
68502 |
| Conditions: |
|
Overweight - Obesity |
| Purpose: |
|
The purpose of this study is to determine how VI-0521 affect speed and reaction time on
specific tasks that require eye and hand coordination, compared to placebo.
|
| Study summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- Written consents;
- Adequate contraception from screening through 28 days after the last dose of study
drug for female subjects;
- Healthy obese or overweight subjects with BMI between 27 and 35.
Exclusion Criteria:
- History of glaucoma or any past or present use of medications to treat increased
intraocular pressure;
- Current use of any tobacco products, including cigarettes, cigars, pipes, or chewing
tobacco, or use within the three months prior to screening;
- History of drug abuse during the three years prior to screening;
- History of alcohol abuse, or excessive alcohol consumption, or describes themselves
as non-users of alcohol;
- Current depression of moderate or greater severity, or any presence or history of
suicidal behavior or active suicidal ideation
- More than one lifetime episode of major depression;
- Currently working night shifts at a job;
- On average consumes greater than two cups of coffee or xanthine-containing beverages
per day (>200 mg/day) within the two weeks prior to screening;
- Any use of dietary, herbal, and/or fitness/body-building supplements (with the
exception of vitamins) within one month prior to screening;
- Aspartate aminotransferase or alanine aminotransferase >2.5 x ULN;
- Serum creatinine ≥1.5 mg/dL for men or ≥1.4 mg/dL for women. |
|
|
|
|
|
|
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
November 4, 2009 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical trials are medical research studies designed to test the safety and/or
effectiveness of new drugs, devices, or treatments in humans. These studies are
conducted worldwide for a range of conditions and illnesses. Learn more about
clinical research and participating in a study at
About Clinical Trials.
|
|
|
|
|